Table 2.
Laboratory data in NPHPT patients with and without renal calcifications.
| Renal calcifications (urolithiasis/nephrocalcinosis) | |||||
|---|---|---|---|---|---|
| Variable | N | Normal range | Present (N = 9) | Absent (N = 25) | P |
| Serum PTH∗∗ (pg/mL) | 34 | 15–65 | 137.00 (104.10; 249.90) | 86.40 (81.15; 113.80) | 0.001 |
| Serum 25(OH)D (ng/mL) | 34 | 30–60 | 37.20 ± 6.92 | 39.65 ± 9.53 | 0.571 |
| Serum 1.25(OH)2D∗∗ (pg/mL) | 17 | 18–72 | 96.83 ± 20.00 (20.65) | 62.36 ± 21.24 (34.06) | 0.005 |
| Serum calcium (mg/dL) | 34 | 8.4–10.4 | 9.69 ± 0.67 | 9.22 ± 0.57 | 0.052 |
| Serum phosphate (mg/dL) | 34 | 2.5–4.5 | 3.13 ± 0.38 | 3.57 ± 0.59 | 0.041 |
| eGFR (mL/min/1.73 m2) | 34 | >60 | 91.11 ± 13.61 | 83.76 ± 12.68 | 0.153 |
| Urinary calcium∗∗ (mg/24 h) | 34 | <250 | 160.00 (122.50; 248.55) | 116.00 (57.00; 183.50) | 0.037 |
| Urinary pH | 34 | 5.5–7.5 | 6.62 ± 0.40 | 6.36 ± 0.51 | 0.195 |
Data are presented as mean ± SD or median (interquartile range). ∗∗PTH, parathyroid hormone; 25OHD, 25-hydroxyvitamin D; 1.25(OH)2D, 1.25-dihydroxyvitamin D.